|Bid||1.5500 x 900|
|Ask||2.6800 x 1000|
|Day's range||2.1702 - 2.4154|
|52-week range||1.3600 - 3.9900|
|Beta (5Y monthly)||2.08|
|PE ratio (TTM)||N/A|
|Earnings date||09 Nov 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||15.00|
- Launch of Ghryvelin™ in a number of key countries in the European Economic Area - Approval of Macrilen® in South Korea in September - Ended the quarter with $38.8 million in cash, expected to fund operations and advancement of priority pipeline programs into 2025 TORONTO, ONTARIO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmac
Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of 40.23% and 104.18%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Aeterna Zentaris (AEZS) announces halting sales of adult growth hormone deficiency diagnosis drug, Macrilen, in the United States in the absence of a commercialization partner. Stock down 5%.